Abstract:8580 Background: EGFR exon 19 deletions (19Del) in non-small cell lung cancer are associated with benefit from tyrosine kinase inhibitors (TKIs), but the relative inhibitor sensitivity of individual EGFR 19Del is unknown. This study predicted the structural features and TKI sensitivity of different EGFR 19Del, compared the clinical efficacy of different TKIs in non-small cell lung cancer (NSCLC) patients harboring EGFR 19Del, and incorporated structural and clinicopathological variables into a nomogram to predict the progression-free survival (PFS) of NSCLC patients with EGFR 19Del. Methods: 1964 patients with advanced NSCLC harboring EGFR 19Del treated with EGFR TKIs from March 2016 to March 2023 were retrospectively screened. Computational model generation and molecular dynamics simulation were used to predict the structural features and TKI sensitivity of different EGFR 19Del variants. Stepwise Cox Proportional Hazards Regression was conducted to select variables for inclusion in the subsequent survival nomogram. Results: A total of 401 patients and 17 subtypes of EGFR 19Del were included in this study. For patients who received first-line 3 rd generation TKIs, E746_A750>X and L746_A750>P had significantly shorter median PFS (mPFS) than other patients (10.6 months vs. 22.6 months, p = 0.0069; 12.8 months vs. 22.6 months, p = 0.027). For patients who received first-line 1 st or 2 nd generation TKIs and second-line TKIs, the PFS was not different among EGFR 19Del. Based on molecular dynamics simulation, E746_A750>X, E746_S752>V, E746_P753>VS and L747_P753>S were grouped into CLASS 1/2G, which had less binding affinity toward 1 st or 2 nd generation TKIs than other EGFR 19Del variants, while E746_A750>X, E746_S752>V, L747_A750>P and L747_T751>P were grouped into CLASS 3G, which had less binding affinity toward 3 rd generation TKIs than other EGFR 19Del variants. For patients who received first-line and second-line 3 rd generation TKIs, CLASS 3G showed shorter mPFS than other patients (12.8 months vs. 22.6 months, p = 0.059; 7.73 months vs. 15.1 months, p = 0.041). For patients who received first-line and second-line 1 st or 2 nd generation TKIs, the PFS was not different between CLASS 1/2G and other patients. For patients who received first-line 3 rd generation TKIs, a survival nomogram was generated incorporating histology, degree of differentiation and CLASS 3G. For patients who received first-line 1 st or 2 nd generation TKIs, a survival nomogram was generated incorporating age, degree of differentiation, liver metastases and number of metastasized organs. Conclusions: We identified a group of EGFR 19Del responded poorly to 3 rd generation TKIs based on structural features. Nomogram that incorporated structural and clinicopathological variables was a robust prognostic model. This study highlights the molecular structural analysis as a useful predictive tool of TKIs efficacy.

Development of Genetic Profiles-Based Nomograms for Predicting Survival among EGFR-mutant Lung Cancer.

Development of Nomograms to Predict Therapeutic Response and Prognosis of Non-Small Cell Lung Cancer Patients Treated with Anti-Pd-1 Antibody

Identification of Nomogram Associated with Durable Clinical Benefit Gene for Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Immunotherapy

Establishment of prognostic nomograms for predicting the progression free survival of EGFR ‐sensitizing mutation, advanced lung cancer patients treated with EGFR‐TKIs

Development and Validation of a Radiomics Nomogram for Progression-Free Survival Prediction in Stage IV EGFR-mutant Non-Small Cell Lung Cancer.

Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status

An Integrative Scoring System for Survival Prediction Following Gefitinib Therapy in Non-Small Cell Lung Cancer: from a Long-Term Real-World Study.

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

A Nomogram for Predicting Brain Metastases of EGFR-mutated Lung Adenocarcinoma Patients and Estimating the Efficacy of Therapeutic Strategies.

Structure-based classification and nomogram prediction for differential inhibitor sensitivity of EGFR exon 19 deletions.

Nomograms To Predict The Presence Of Egfr Mutations And Alk Rearrangements In Non-Small-Cell Lung Carcinoma

PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs

Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers

Nomogram prediction for epidermal growth factor receptor mutation and subtypes in patients with non-small cell lung cancer

Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer

P1.01-92 Underlying Mechanisms That Potentially Affect Prognosis to EGFR-TKI in EGFR-Positive Patients with Non-Small Cell Lung Cancer

Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC

Specific TCR Profiles Predict Clinical Outcome of Adjuvant EGFR-TKIs for Resected EGFR -Mutant Non-Small Cell Lung Cancer